Algo sobre criterios indirectos de validación

Referencias:

1. Cleophas TJ, Zwinderman AH, Chaib AH. Novel procedures for validating surrogate endpoints in clinical trials. Current Clinical in Pharmacology. 2007; 2(2):123-8.
2. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol. 2005;105 (5 Pt 1):1114-8.
3. Manns B, Owen WF Jr, Winkelmayer WC, Devereaux PJ, Tonelli M. Surrogate markers in clinical studies: problems solved or created? American Journal of Kidney Diseases. 2006 ;48(1):159-66.
4. Prentice RL. Surrogate and mediating endpoints: current status and future directions. Journal of National Cancer Institute. 2009; 101(4):216-7.
5. Cleophas TJ, Zwinderman AH, Chaib AH. Novel procedures for validating surrogate endpoints in clinical trials. Current Clinical in Pharmacology. 2007; 2(2):123-8.
6. Wu W, Shi Q, Sargent DJ. Statistical considerations for the next generation of clinical trials. Seminars in Oncology. 2011; 38(4):598-604.